going on here. This is like a phoenix rising from the ashes. Guess nobody monitoring this board has a clue, but if you have been watching for over a year, like myself, you'll have to agree that this action and volume are precluding something. I'm gonna guess we'll know right after the first of the year and I'm also gonna guess it's a prop-up to keep the tax loss selling down.
ursus stated on the 9/23/04 investment letter
"We are lowering our price target from$6-$4 to account for added uncertainty surrounding apf112". if the stock nears $4 i would be selling the stock. if i recieve some info from ursus stating that things have changed their view on appa, i will post it
While I will hold APPA for prices in the $3 range, unless their fundamentals improve with something like a strong partnership with big pharma, I would appreciate if you would post the sell signal from ursus, and their reasons, -- AFTER you sell, of course:)
i gave this board some information i got from a medical news letter provided to me from ursus capital, a biotec fund. they made the call on appa, not me. you sound like you may have lost a few bucks investing in appa, i don't know or care if you have. i will sell appa when the fund sells it. as for your view that it will trade below 1.23, i would trust ursus way before i would trust you. why, because you provide NO meaningful info.
"i invest with a biotec hedge fund, ursus capital, these guys have rec this stock on several occations, based on valuation. much more than that, i can say. "
We, as higher beings than you, will decipher what you intended to write there.
You wanted to close with.."Much more than that I CAN'T say." Perhaps eluding to you having some knowledge that would not be common.
We got that much, even though you didn't.
Sorry, I have some bad news for you, Charlie.
You have been suckered by a large group of people. Hope that eases the pain for you.
I would say a better explanation is that this stock is currently under-valued. If someone or some institution is trying to "prop" up the price, you would expect no more than around the opening price to be the benchmark. You certainly wouldn't expect to see them grow it by 15% or whatever its at now.
Increased Market share and Revenue streams from CARAC and RETIN-A plus feedback that the bioerodable deliver polymers really work, and aren't addling the patient. Thats a pretty god bet, albeit with some risk, but at this price, looks like some folks still view it as a bargain. Than again maybe they do know something good we don't know.